The Board of Directors
Lars Jonsson is a licensed physician with a doctorate in anesthesia and intensive care. In addition to long-standing clinical and academic activities, Lars Jonsson was the CEO of Uppsala University Holding AB (UUAB), between 1998 and 2018. During that period, Lars Jonsson was involved in more than 90 start-ups and spin-offs from Uppsala University, in many of which he served as either chairman or board member.
Holdings: 26,000 shares, 26 500 warrants
Jarl Wikberg is a Doctor of Medicine with a doctorate in medical pharmacology from Linköping University. He has many years of academic experience as a teacher, researcher and professor at several different universities. Jarl Wikberg has founded several companies related to the pharmaceutical industry, and has extensive experience in research and scientific production. Jarl Wikberg is the founder of Dicot and discovered Libiguin®.
Holdings: 4,071,770 shares, personally and through Dicotyledon AB
Lena Söderström holds a bachelor's degree in medical science and an Executive MBA from Uppsala University. Lena Söderström has 30 years of experience as an executive in international pharmaceutical and medical technology companies, with senior positions in project management, business development, international marketing and manufacturing. She is also a representative of the Stockholm Chamber of Commerce and a board member of Uppsala University Holding AB (UUAB) and chairman of SLU Holding AB.
Holdings: 7,750 warrants
Mikael von Euler is an M.D with a PhD from the Karolinska Institute. Mikael von Euler is an oncologist with more than 25 years of experience in the pharmaceutical industry. He was previously CMO (Chief Medical Officer) at Oncos Therapeutics (now Targovax), and SVP (Senior Vice President) at Aprea Therapeutics. He has held several senior positions in major pharmaceutical companies: He was the Cluster Head at Roche / Genentech, Vice President Oncology Europe at GlaxoSmithKline and Global Product Director for Arimidex / Nolvadex at AstraZeneca.
Holdings: 7,750 warrants
Ebba Florin-Robertsson, has more than 30 years of experience in drug development within the Kabi-Pharmacia-Biovitrum-Sobi conglomerate, where she has held a number of different positions: line manager of pharmacy, project manager for CMC (Chemistry, Manufacturing and Controls) in a number of both internal and external development projects, and specialist / generalist working with several commercial products, regulatory documentation and business development. She has published a number of scientific articles and has about 25 patents / patent applications.
Holdnings: 10,000 warrants